{
    "eid": "2-s2.0-85169817982",
    "title": "Adjunctive daratumumab can induce rapid remission in acquired haemophilia A with poor prognostic markers",
    "cover-date": "2023-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Hematology",
            "@code": "2720",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Genetics (clinical)",
            "@code": "2716",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [],
    "authors": [
        "Chatphatai Moonla",
        "Chantana Polprasert",
        "San Krittikarux",
        "Nuanrat Cheerasiri",
        "Benjaporn Akkawat",
        "Ponlapat Rojnuckarin",
        "Noppacharn Uaprasert"
    ],
    "citedby-count": 0,
    "ref-count": 11,
    "ref-list": [
        "Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study",
        "International recommendations on the diagnosis and treatment of acquired hemophilia A",
        "Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)",
        "Rituximab and bortezomib for patients with newly diagnosed acquired heamophilia: single arm, single center, prospective phase 2 study",
        "On the road to eliminating long-lived plasma cells\u2014\u201care we there yet?\u201d",
        "Daratumumab rapidly reduces high-titre factor VIII inhibitors in haemophilia A patients during life-threatening haemorrhages",
        "Reduced-intensity, risk factor-stratified immunosuppression for acquired hemophilia A: single-center observational study",
        "Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients",
        "Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma",
        "Anti-CD38 antibody for refractory acquired hemophilia A",
        "Emicizumab for the treatment of acquired hemophilia A"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Sakaeo",
            "@id": "60008445",
            "affilname": "Sakaeo Crown Prince Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60008445",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": []
}